Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reslizumab in Hypereosinophilic Syndrome and Eosinophilic Gastroenteritis
NCT00017862Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2001
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of reslizumab in hypereosinophilic syndrome (HES) and eosinophilic gastroenteritis (EGE), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Reduction in peripheral blood eosinophilia at 1 year and Safety and side effects at 1 year. Started Jun 2001; status: completed.
02
Drugs
reslizumab
03
Conditions
hypereosinophilic syndrome (HES)eosinophilic gastroenteritis (EGE)
Beyond the preview
Go deeper on NCT00017862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00017862.